2 completed, 1 recruiting, 1 terminated. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
Follow Heidelberg Pharma AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma HDP-101 - Multiple Myeloma, Plasma Cell Disorder | Phase 1 / Phase 2 | Recruiting | Heidelberg Pharma AG | 78 | 2022-02-07 | 2026-09-17 |
| Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours WX-554 - Advanced Solid Tumours | Phase 1 / Phase 2 | Terminated | Heidelberg Pharma AG | 41 | 2012-03-01 | 2014-05-16 |
| Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer WX-671, placebo - Metastatic Breast Cancer | Phase 2 | Completed | Heidelberg Pharma AG | 132 | 2008-07-01 | 2014-02-28 |
| Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery gemcitabine hydrochloride, Serine Proteinase Inhibitor WX-671 - Pancreatic Cancer | Phase 2 | Completed | Heidelberg Pharma AG | 95 | 2007-04-01 | 2012-03-29 |
Breast Neoplasms (1) · Multiple Myeloma (1) · Neoplasms, Plasma Cell (1) · Pancreatic Neoplasms (1)
upamostat (2) · Gemcitabine (1)
Germany (3) · Hungary (2) · United States (2) · Belgium (1) · Brazil (1) · Israel (1) · Italy (1) · Poland (1) · Romania (1) · Russia (1) · Spain (1) · Ukraine (1) · United Kingdom (1)
Carola Mala, PhD (1) · Lori Goldstein, MD (1) · Nadia Harbeck, MD (1) · Ruth Plummer, MD (1)